Nebivolol

Introduction Overview

Generic Name

nebivolol

Brand Name

Bystolic

Dosage Form

oral tablet (2.5 mg; 5 mg; 10 mg; 20 mg)

Drug Class

Cardioselective beta blockers

Pharmacokinetics

Absorption:
Nebivolol is well absorbed orally with peak plasma concentrations typically attained within 1 to 4 hours after administration. Its bioavailability exhibits interindividual variability due to extensive first-pass metabolism. Food does not significantly affect the rate or extent of absorption, allowing administration with or without food. Clinical studies indicate that steady-state plasma levels are reached within 7 to 10 days of once-daily dosing.

Distribution:
Nebivolol demonstrates moderate plasma protein binding (approximately 98%) predominantly to albumin and α1-acid glycoprotein. It has a moderate volume of distribution, indicating distribution primarily into extracellular fluid spaces. Nebivolol is lipophilic enough to cross cellular membranes but maintains cardioselectivity partly due to preferential binding to beta-1 adrenergic receptors concentrated in cardiac tissue. Limited penetration across the blood-brain barrier contributes to its lower incidence of central nervous system side effects compared with non-selective beta blockers.

Metabolism:
Nebivolol undergoes extensive hepatic metabolism primarily via the cytochrome P450 isoenzyme CYP2D6. It is metabolized into multiple inactive and a few active metabolites, including hydroxylated derivatives. There is significant genetic polymorphism in CYP2D6 activity, classifying individuals as poor or extensive metabolizers; poor metabolizers exhibit increased plasma concentrations and prolonged half-life. This metabolic variability necessitates careful dose titration to avoid adverse effects in poor metabolizers. Hepatic impairment may reduce metabolism and alter drug clearance.

Elimination:
The elimination half-life of nebivolol averages 12 hours in extensive metabolizers and up to 19 hours in poor metabolizers. Excretion occurs via renal and fecal routes; approximately 38% of the dose is recovered in urine mostly as metabolites, and the remainder is eliminated in feces. The drug and its metabolites do not accumulate significantly with repeated dosing due to balanced metabolism and elimination processes. Dose adjustments may be warranted in severe hepatic impairment but less so in renal dysfunction, as clearance is less affected by renal status.

Dosage Forms

Available Dosage Forms:
Nebivolol is commercially available as oral tablets in multiple strengths to allow flexible dosing and titration. The available tablet strengths include 2.5 mg, 5 mg, 10 mg, and 20 mg. These tablets are intended for once-daily oral administration.

Dosages for Adults and Adolescents:
The typical initial dosing for adult patients with hypertension is 5 mg once daily. Dose adjustments are usually made based on blood pressure response and tolerability, with titration intervals of at least 2 weeks to monitor for efficacy and side effects. The dose can be increased up to a maximum of 40 mg once daily in some cases, although such high doses are not commonly used and should be individualized. The dose should be modified for specific patient needs depending on therapeutic response.

Specific Patient Populations:
In patients with hepatic impairment, dosage reduction and careful monitoring are necessary due to decreased metabolic clearance. Elderly patients typically start at lower doses and require cautious titration. No specific pediatric dosing recommendations are established; nebivolol use in adolescents should be approached with clinical discretion. Patients with renal impairment generally do not require dose adjustment due to minimal renal clearance impact. Regular monitoring is advised in all populations to ensure safety and efficacy.

Mechanism Of Action

Nebivolol is a highly selective beta-1 adrenergic receptor antagonist with additional vasodilatory properties mediated through nitric oxide (NO) release. By selectively blocking beta-1 receptors in myocardial tissue, nebivolol reduces heart rate, myocardial contractility, and cardiac output, culminating in decreased blood pressure and reduced cardiac workload. This cardioselectivity minimizes bronchoconstriction and other beta-2 related side effects common with non-selective beta blockers.

Beyond beta-1 blockade, nebivolol uniquely stimulates endothelial nitric oxide synthase (eNOS), leading to increased production of nitric oxide, a potent vasodilator. This NO-mediated vasodilation enhances peripheral arterial compliance and reduces systemic vascular resistance independent of heart rate or contractility. This dual mechanism contributes to nebivolol's antihypertensive effects and benefits in improving endothelial function.

At the cellular level, nebivolol inhibits the cAMP-mediated signaling pathways via beta-1 receptor antagonism, reducing calcium influx into cardiac muscle cells and downregulating renin release from juxtaglomerular cells. The enhanced NO release further induces cyclic GMP production in vascular smooth muscle cells, promoting relaxation and vasodilation. This combined action helps restore vascular homeostasis and attenuates pathological remodeling.

Clinical studies have demonstrated that nebivolol effectively lowers blood pressure with a favorable side effect profile owing to its vasodilatory effects and selectivity. Compared with other beta blockers such as atenolol and metoprolol, nebivolol's NO-mediated vasodilation provides added benefits in improving arterial compliance and reducing peripheral resistance, potentially translating to improved cardiovascular outcomes and better tolerability. These properties have been well documented in randomized controlled trials and observational studies.

Pharmacological Actions

Selective beta-1 adrenergic receptor antagonist activity reducing heart rate and myocardial contractility
Vasodilation mediated by stimulation of endothelial nitric oxide release
Reduction of systemic vascular resistance and blood pressure
Decrease in cardiac output contributing to antihypertensive effects
Improvement in endothelial function and arterial compliance
Inhibition of renin release from the kidneys, reducing RAAS activation
Minimal beta-2 receptor blockade, resulting in fewer bronchospastic effects
Antihypertensive effects suitable for monotherapy or combination therapy
Reduction of myocardial oxygen demand by lowering heart rate
Potential protective effects against cardiac remodeling in hypertensive patients
Moderate lipophilicity allowing central nervous system penetration without significant CNS adverse effects
Favorable pharmacokinetics enabling once-daily dosing
Metabolized extensively in the liver with variable half-life based on CYP2D6 polymorphisms
Exerts antioxidant properties via nitric oxide pathways
Demonstrates a balanced profile between negative inotropy and vasodilation

Therapeutic Or Clinical Uses

Management of essential hypertension to reduce elevated blood pressure
Prevention of stroke and myocardial infarction associated with hypertension
Reduction of cardiovascular morbidity and mortality in hypertensive patients
Use as monotherapy or in combination with other antihypertensive agents
Potential off-label use for tachyarrhythmias due to beta-1 blockade
Treatment of heart conditions where beta-1 blockade is beneficial, avoiding non-selective beta effects
Improvement of endothelial function in patients with vascular dysfunction
Alternative beta blocker for patients intolerant to other agents due to vasodilatory effects
Management of hypertension in patients with coexisting type 2 diabetes (with caution)
Adjunct therapy in heart failure patients with preserved ejection fraction (investigational use)
Use in elderly patients requiring gentle heart rate reduction and blood pressure control
Treatment of hypertensive patients with peripheral vascular disease due to minimal beta-2 blockade
Control of hypertension during perioperative management as part of comprehensive care
Management of increased sympathetic drive in certain autonomic disorders
Potential protective benefits against renal damage secondary to hypertension

Side Or Adverse Effects

Dizziness due to blood pressure lowering and potential orthostatic hypotension
Fatigue or tiredness commonly reported during initial treatment phase
Bradycardia or slow heart rate which may require dose adjustment
Peripheral edema, particularly in lower extremities
Headache attributed to vasodilatory or blood pressure effects
Cold extremities or numbness due to peripheral vasoconstriction
Shortness of breath, especially in patients with underlying pulmonary disease
Hypotension, particularly with dose escalations or in volume-depleted patients
Light-headedness or syncope from excessive heart rate or blood pressure reduction
Gastrointestinal disturbances including nausea or vomiting (less common)
Allergic reactions including rash and, rarely, angioedema
Worsening of pre-existing asthma or bronchospasm in sensitive individuals
Sexual dysfunction including decreased libido or erectile difficulties
Sleep disturbances such as insomnia or vivid dreams (rare)
Potential masking of hypoglycemia symptoms in diabetic patients

Precautions

Use cautiously in patients with a history of severe heart failure or decompensated cardiac conditions
Monitor heart rate and rhythm regularly to avoid symptomatic bradycardia
Avoid abrupt discontinuation to prevent rebound hypertension and tachycardia
Use with caution in patients with hepatic impairment due to altered metabolism
Careful dose titration in elderly patients due to altered pharmacodynamics
Watch for signs of worsening peripheral vascular disease or Raynaud’s phenomenon
Cautious use in diabetic patients due to potential masking of hypoglycemia symptoms
Evaluate pulmonary status in patients with reactive airway diseases before initiation
Adjust dose or avoid use in patients with second- or third-degree atrioventricular block unless pacemaker is present
Avoid use in patients with sick sinus syndrome without pacemaker
Use cautiously in patients with thyroid disorders, notably untreated thyrotoxicosis
Monitor renal function periodically in patients with chronic kidney disease
Regular blood pressure monitoring to adjust therapy and detect hypotensive episodes
Avoid use during pregnancy unless clearly needed after risk-benefit evaluation
Contraindicated during breastfeeding due to insufficient safety data

Warnings

Do not discontinue nebivolol abruptly; sudden withdrawal may precipitate serious cardiac events including myocardial infarction
Use is contraindicated in patients with severe bradycardia or heart block without pacemaker
Avoid in patients with severe hepatic impairment due to risk of accumulation and toxicity
Potential for severe allergic reactions including anaphylaxis; seek emergency help if signs appear
Careful consideration in patients with bronchospastic disease to avoid exacerbations
May cause hypotension leading to falls, especially in elderly or debilitated patients
Monitor for signs of worsening heart failure during treatment
Patients should inform surgeons about nebivolol use prior to any surgery due to interactions with anesthesia
Masking of hypoglycemic symptoms requires vigilance in diabetic patients
Avoid use during pregnancy unless benefits outweigh potential fetal risks
Breastfeeding is not recommended during treatment due to lack of safety data
May impair patient's ability to drive or operate machinery until individual response is known
Potential drug interactions can increase side effect risk or reduce efficacy; inform healthcare providers of all medications
Careful dose titration and blood pressure monitoring is essential to avoid adverse cardiovascular events
In patients with pheochromocytoma, use only in combination with alpha-blockade to prevent hypertensive crises

Contraindication

Known hypersensitivity to nebivolol or any component of the formulation
Severe bradycardia (heart rate less than 50 bpm)
Second- or third-degree atrioventricular block without a pacemaker
Sick sinus syndrome without pacemaker
Cardiogenic shock or unstable heart failure
Severe hepatic impairment
Decompensated heart failure requiring intravenous inotropic therapy
Symptomatic hypotension
Severe peripheral arterial circulatory disorders
Pregnancy unless benefits clearly outweigh risks
Breastfeeding due to insufficient safety information
Concurrent use with certain CYP2D6 inhibitors requiring dose adjustments
Pheochromocytoma without alpha blockade
Severe asthma or chronic obstructive pulmonary disease with bronchospastic components
Patients with untreated or uncontrolled thyroid disorders

Drug Interactions

Beta-agonists may antagonize the antihypertensive effect of nebivolol
Other antihypertensive agents can potentiate hypotensive effects leading to excessive blood pressure reduction
CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) can increase plasma concentrations of nebivolol requiring dose adjustment
Calcium channel blockers (verapamil, diltiazem) may have additive negative chronotropic and inotropic effects
Digoxin levels may be increased when combined with nebivolol, enhancing risk of bradycardia
Antiarrhythmic agents may increase risk of conduction abnormalities when used concomitantly
Non-steroidal anti-inflammatory drugs (NSAIDs) may reduce antihypertensive efficacy
Insulin and oral hypoglycemics' effect on blood glucose may be masked necessitating closer monitoring
Anesthesia agents may interact causing unpredictable cardiovascular responses
Clonidine withdrawal while on nebivolol can cause severe hypertension; gradual withdrawal recommended
Potassium-sparing diuretics/polymerase inhibitors may increase risk of hyperkalemia
Certain antidepressants and antipsychotics with cardiac effects require cautious co-administration
Avoid abrupt combination with alpha-blockers due to additive hypotensive effects
Alcohol may enhance hypotensive effects leading to dizziness or syncope
Drugs that prolong QT interval require careful monitoring to prevent arrhythmias

Preparations Of The Drug

Oral tablets available in 2.5 mg strength for initiation and titration
Oral tablets available in 5 mg strength as standard maintenance dose
Oral tablets available in 10 mg strength for dose escalation in resistant cases
Oral tablets available in 20 mg strength for maximal titration when clinically justified
Tablets formulated for once-daily dosing with sustained antihypertensive effect
Each tablet contains nebivolol hydrochloride in immediate-release formulation
Tablets are film-coated to facilitate swallowing and mask bitterness
Packaged in blister packs to protect from moisture and degradation
Storage recommended at controlled room temperature, away from heat and moisture
No parenteral or liquid formulations commercially available currently
Prescribed as monotherapy or fixed-dose combination with other antihypertensives in some markets
Manufactured in compliance with Good Manufacturing Practice (GMP) ensuring consistent drug quality
Available under brand name Bystolic with manufacturer-provided patient information leaflets
Generic formulations available with verified bioequivalence to branded preparations
Standard labeling includes warnings about contraindications, precautions, and adherence importance